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Carotid atherosclerosis can be detected by ultrasound
and is a risk factor for myocardial infarction and
stroke.1,2 It is a consequence of endothelial dysfunc-
tion;3 thus, understanding the role that the endothe-
lium plays in maintaining vascular tone has provided
new insights into the evaluation and treatment of
atherosclerosis. Some of the most important vasoactive
substances produced by the endothelium are nitric
oxide (NO) and NO-containing donors. NO exerts its
vasodilatory effect by activating guanylate cyclase, a
major cellular initiator of vascular relaxation.4
Endothelial dysfunction has not been well studied
in patients with carotid atherosclerosis. However, Hsu
et al5 used brachial-artery flow-mediated dilatation
(FMD), a promising, noninvasive tool for detecting en-
dothelial dysfunction, to evaluate endothelial dysfunc-
tion in patients with carotid atherosclerosis, and found
that systemic endothelial dysfunction might contribute
to atherosclerosis in these patients. The authors also
evaluated changes in FMD, cytokines and carotid
arterial stenosis during atorvastatin administration to
patients with normocholesterolemia.6 The investiga-
tors found that endothelial dysfunction was significant-
ly improved after 4 months of atorvastatin treatment.
However, the 2 questions below should be posed.
Is the assessment of brachial-artery
FMD reliable and reproducible?
In the 1990s, high-frequency ultrasound imaging of
the brachial artery to assess endothelium-dependent
FMD was developed.7 Over the past decade, this test
has proved to be a quantitative, noninvasive and re-
producible means of detecting the severity of endo-
thelial dysfunction. The sensitivity, specificity and pos-
itive predictive value for brachial-artery FMD were
71%, 81%, and 95%, respectively.8 Nonetheless, the
measurement of brachial FMD has some limitations.
Firstly, measurement of brachial-artery diameter is
difficult, and intraobserver variations exist. Secondly,
with the wide baseline variability that exists in a nor-
mal response to increased flow, the present techniques
may fail to detect the true peak FMD. Thirdly, there is
currently no standardized “normal range” for FMD.
Fourthly, brachial FMD reflects only 1 facet of en-
dothelial dysfunction; factors such as age, sex, serum
markers of inflammation, and serum markers of vas-
cular homeostasis may all influence endothelial dys-
function. Although no gold-standard method exists
for measuring endothelial dysfunction, brachial-artery
FMD is widely used as a reliable and reproducible
research tool.
If 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors (statins) have direct
anti-inflammatory effects, how long do
they need to achieve significant benefit?
Hsu et al6 found that atorvastatin significantly decreased
serum levels of total and low-density lipoprotein (LDL)
cholesterol after 1, 2 and 4 months’ treatment, although
levels of inflammatory cytokines showed no significant
reduction within 4 months, suggesting that longer
periods of statin therapy may be needed to cause sig-
nificant anti-inflammatory effects. However, Albert
et al9 reported that pravastatin had anti-inflammatory
effects, as evident from reduced levels of C-reactive
protein (CRP) at 12 and 24 weeks. Ridker et al10
reported that CRP levels were significantly reduced
within 8 weeks of starting cerivastatin therapy. Although
levels of inflammatory cytokines were not significantly
reduced in the study by Hsu et al,6 a trend towards a
progressive reduction after atorvastatin use was demon-
strated. Furthermore, if the latter study had continued
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beyond 4 months, atorvastatin might have displayed
significant anti-inflammatory effects.
Summary
The assessment of brachial-artery FMD is a reliable,
reproducible and noninvasive tool for evaluating
endothelial dysfunction, which, together with endo-
thelial inflammation, causes carotid atherosclerosis.
Atorvastatin therapy can reverse endothelial dysfunc-
tion after 4 months, and may have significant anti-
inflammatory effects if continued for more than 4
months. Importantly, statin therapy can be used to
treat carotid atherosclerosis.
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